BridgeMD
New treatment option for Non-Small Cell Lung Cancer
Official title Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT07632365
What this study is testing
What is Induction chemoimmunotherapy?
Induction chemoimmunotherapy is an investigational medicine, being studied as a potential treatment for non-small cell lung cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Phase I consists of a single-arm safety lead-in study evaluating the safety and preliminary efficacy of the investigational regimen.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \>18 years, male or female, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
- Unresectable stage III NSCLC (according to the 8th edition of the AJCC staging system).
- No prior exposure to any other anti-tumor therapy.
- Absence of severe medical comorbidities or major organ dysfunction, as assessed by hematology, hepatic, renal, cardiac, and pulmonary function tests...
You likely can't join if
- Presence of small cell carcinoma components in the histological examination results.
- Co-occurrence of EGFR mutation, ALK rearrangement, or ROS-1 rearrangement positivity.
- History of other primary malignancies, with the following exceptions: Malignancies treated with curative intent with no known active disease and low...
- Active or documented history of autoimmune or inflammatory diseases (including inflammatory bowel disease [e.g., colitis or Crohn's disease]...
- History of allogeneic organ transplantation.
- History of active primary immunodeficiency.
See the full eligibility criteria
- Age \>18 years, male or female, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
- Unresectable stage III NSCLC (according to the 8th edition of the AJCC staging system).
- No prior exposure to any other anti-tumor therapy.
- Absence of severe medical comorbidities or major organ dysfunction, as assessed by hematology, hepatic, renal, cardiac, and pulmonary function tests, meeting the following criteria: Hematology: Hemoglobin (HB) ≥ 90 g/L...
- Life expectancy ≥ 3 months.
- Adequate understanding of the study, ability to complete treatment, suitability for follow-up, and voluntary provision of written informed consent.
- Presence of small cell carcinoma components in the histological examination results.
- Co-occurrence of EGFR mutation, ALK rearrangement, or ROS-1 rearrangement positivity.
- History of other primary malignancies, with the following exceptions: Malignancies treated with curative intent with no known active disease and low potential for recurrence for ≥5 years prior to the first dose of...
- Active or documented history of autoimmune or inflammatory diseases (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [excluding diverticulosis], systemic lupus erythematosus...
- History of allogeneic organ transplantation.
- History of active primary immunodeficiency.
- Presence of uncontrolled concurrent illness, including but not limited to persistent or active infection (including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus [HIV], etc.), symptomatic...
- Female patients who are pregnant or breastfeeding.
- Concurrent or prior use of immunosuppressive medication within 14 days prior to the first dose of induction immunotherapy. Exceptions include: intranasal, inhaled, or topical corticosteroids, or local corticosteroid...
- Known allergy or hypersensitivity to any study drug or any excipient of a study drug.
- Patients judged by the investigator to be unable to comply with study procedures, restrictions, and requirements.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Xuhui, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Xuhui, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.